CellTrans’ Donislecel Gets US FDA Panel Nod For Small Group Of Type 1 Diabetics

Benefits of independence from exogenous insulin outweighed the risks from long-term immunosuppression necessary with the allogeneic pancreatic islet cellular therapy, majority of panelists said, but they urged the FDA to limit the indication to a very small subpopulation of patients.